# Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

> **NCT00924040** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Hairy Cell Leukemia

## Interventions

- **DRUG:** BL22 (CAT-3888)

## Key facts

- **NCT ID:** NCT00924040
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new supply.
- **Last updated:** 2015-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00924040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00924040, "Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00924040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*